Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 99.4 Million EUR | 344.54% |
| 2022 | -40.64 Million USD | -34.9% |
| 2021 | -30.13 Million EUR | 30.36% |
| 2020 | -43.26 Million EUR | -168.25% |
| 2019 | -16.13 Million EUR | -91.02% |
| 2018 | -8.44 Million EUR | -131.09% |
| 2017 | 27.16 Million EUR | -27.25% |
| 2016 | 37.33 Million EUR | 316.46% |
| 2015 | -17.25 Million EUR | 56.48% |
| 2014 | -39.63 Million EUR | -91.41% |
| 2013 | -20.7 Million EUR | -547.78% |
| 2012 | -3.19 Million EUR | -616.94% |
| 2011 | -445.85 Thousand EUR | 96.75% |
| 2010 | -13.7 Million EUR | -171.55% |
| 2009 | 19.15 Million EUR | -24.23% |
| 2008 | 25.27 Million EUR | 149.2% |
| 2007 | -51.37 Million EUR | -58.86% |
| 2006 | -32.33 Million EUR | -88.3% |
| 2005 | -17.17 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 74.88 Million EUR | -25.45% |
| 2024 Q3 | 34.75 Million USD | -22.74% |
| 2024 Q1 | 115.31 Million USD | 5.02% |
| 2023 FY | 99.4 Million EUR | 344.54% |
| 2023 Q4 | 109.8 Million USD | 0.43% |
| 2023 Q3 | 109.33 Million USD | 591.62% |
| 2023 Q2 | -22.23 Million USD | -54.64% |
| 2023 Q1 | -14.38 Million USD | 64.62% |
| 2022 Q4 | -40.64 Million USD | 17.92% |
| 2022 Q2 | -40.96 Million USD | -28.46% |
| 2022 Q3 | -49.52 Million USD | -20.89% |
| 2022 FY | -40.64 Million USD | -34.9% |
| 2022 Q1 | -31.88 Million USD | -19.81% |
| 2021 Q2 | -17.92 Million EUR | 65.96% |
| 2021 FY | -30.13 Million EUR | 30.36% |
| 2021 Q3 | -18.52 Million EUR | -3.33% |
| 2021 Q4 | -26.61 Million EUR | -43.7% |
| 2021 Q1 | -52.64 Million EUR | -21.68% |
| 2020 FY | -43.26 Million EUR | -168.25% |
| 2020 Q1 | -7.24 Million EUR | 55.06% |
| 2020 Q2 | -26.85 Million EUR | -270.46% |
| 2020 Q3 | -29.06 Million EUR | -8.23% |
| 2020 Q4 | -43.26 Million EUR | -48.86% |
| 2019 Q4 | -16.13 Million EUR | -508.46% |
| 2019 Q3 | -2.65 Million EUR | -234.85% |
| 2019 FY | -16.13 Million EUR | -91.02% |
| 2019 Q2 | 1.96 Million EUR | -71.77% |
| 2019 Q1 | 6.96 Million EUR | 182.47% |
| 2018 Q2 | 20.81 Million EUR | -16.15% |
| 2018 Q3 | 7.87 Million EUR | -62.16% |
| 2018 FY | -8.44 Million EUR | -131.09% |
| 2018 Q4 | -8.44 Million EUR | -207.2% |
| 2018 Q1 | 24.82 Million EUR | -8.6% |
| 2017 Q1 | 40.85 Million EUR | 9.42% |
| 2017 FY | 27.16 Million EUR | -27.25% |
| 2017 Q4 | 27.16 Million EUR | -53.78% |
| 2017 Q3 | 58.77 Million EUR | -21.56% |
| 2017 Q2 | 74.92 Million EUR | 83.39% |
| 2016 FY | 37.33 Million EUR | 316.46% |
| 2016 Q1 | -13.7 Million EUR | 20.54% |
| 2016 Q4 | 37.33 Million EUR | 2324.8% |
| 2016 Q2 | -6.12 Million EUR | 55.35% |
| 2016 Q3 | -1.67 Million EUR | 72.58% |
| 2015 Q3 | -20.83 Million EUR | 21.51% |
| 2015 Q1 | -31.3 Million EUR | 21.02% |
| 2015 FY | -17.25 Million EUR | 56.48% |
| 2015 Q2 | -26.54 Million EUR | 15.19% |
| 2015 Q4 | -17.25 Million EUR | 17.22% |
| 2014 Q3 | -28.03 Million EUR | 16.44% |
| 2014 FY | -39.63 Million EUR | -91.41% |
| 2014 Q2 | -33.55 Million EUR | -43.72% |
| 2014 Q4 | -39.63 Million EUR | -41.37% |
| 2014 Q1 | -23.34 Million EUR | -12.75% |
| 2013 Q2 | -5.23 Million EUR | 29.12% |
| 2013 FY | -20.7 Million EUR | -547.78% |
| 2013 Q4 | -20.7 Million EUR | -94.88% |
| 2013 Q3 | -10.62 Million EUR | -103.11% |
| 2013 Q1 | -7.38 Million EUR | -130.88% |
| 2012 Q4 | -3.19 Million EUR | -255.88% |
| 2012 Q1 | -2.29 Million EUR | -415.82% |
| 2012 FY | -3.19 Million EUR | -616.94% |
| 2012 Q3 | 2.05 Million EUR | 0.0% |
| 2011 Q2 | -14.33 Million EUR | 29.88% |
| 2011 Q1 | -20.45 Million EUR | -50.38% |
| 2011 Q3 | -11.85 Million EUR | 17.29% |
| 2011 Q4 | -445.85 Thousand EUR | 96.24% |
| 2011 FY | -445.85 Thousand EUR | 96.75% |
| 2010 Q3 | -7.74 Million EUR | -415.45% |
| 2010 FY | -13.7 Million EUR | -171.55% |
| 2010 Q4 | -13.59 Million EUR | -75.49% |
| 2010 Q2 | 2.45 Million EUR | -87.77% |
| 2010 Q1 | 20.08 Million EUR | 4.86% |
| 2009 FY | 19.15 Million EUR | -24.23% |
| 2009 Q4 | 19.15 Million EUR | 0.0% |
| 2008 FY | 25.27 Million EUR | 149.2% |
| 2007 FY | -51.37 Million EUR | -58.86% |
| 2006 FY | -32.33 Million EUR | -88.3% |
| 2005 FY | -17.17 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 14021.796% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 150.592% |
| Adocia SA | 127 Thousand EUR | -78168.992% |
| Aelis Farma SA | -16.19 Million EUR | 713.893% |
| Biophytis S.A. | 2.7 Million EUR | -3577.455% |
| Advicenne S.A. | 12.17 Million EUR | -716.44% |
| genOway Société anonyme | 2.97 Million EUR | -3243.514% |
| IntegraGen SA | -709.74 Thousand EUR | 14105.179% |
| Medesis Pharma S.A. | 1.15 Million EUR | -8482.349% |
| Neovacs S.A. | -237.08 Thousand EUR | 42026.221% |
| NFL Biosciences SA | -2.27 Million EUR | 4467.632% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -2181.681% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 12068.197% |
| Sensorion SA | 1.37 Million EUR | -7112.308% |
| Theranexus Société Anonyme | 2.44 Million EUR | -3966.911% |
| TME Pharma N.V. | -1.07 Million EUR | 9312.384% |
| Valbiotis SA | -18.13 Million EUR | 647.999% |
| TheraVet SA | 12.78 Thousand EUR | -777386.273% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -4459.707% |
| argenx SE | -1.83 Billion EUR | 105.412% |
| BioSenic S.A. | 28.04 Million EUR | -254.449% |
| Celyad Oncology SA | -6.1 Million EUR | 1729.001% |
| DBV Technologies S.A. | -114.95 Million USD | 186.469% |
| Galapagos NV | -157.2 Million EUR | 163.23% |
| Genfit S.A. | -7.61 Million EUR | 1406.026% |
| GeNeuro SA | 5.91 Million EUR | -1581.809% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 495.833% |
| Innate Pharma S.A. | -30.71 Million EUR | 423.657% |
| Inventiva S.A. | 10.48 Million EUR | -847.675% |
| MaaT Pharma SA | -10.2 Million EUR | 1074.048% |
| MedinCell S.A. | 39.5 Million EUR | -151.643% |
| Nanobiotix S.A. | -24.71 Million EUR | 502.143% |
| Onward Medical N.V. | -12.89 Million EUR | 870.914% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -6849.539% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | -266.404% |
| Oxurion NV | 10.71 Million EUR | -828.12% |
| Poxel S.A. | 44.55 Million EUR | -123.079% |
| GenSight Biologics S.A. | 16.29 Million EUR | -510.05% |
| Transgene SA | -14.4 Million EUR | 789.858% |
| Financière de Tubize SA | 78.62 Million EUR | -26.425% |
| UCB SA | 2.17 Billion EUR | 95.434% |
| Valneva SE | 82.73 Million EUR | -20.143% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 636.61% |